Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins.
Hyku has raised $56.0M in total funding. The most recent round was Seed. The last funding was announced in September 2023.
Hyku's investors include RA Capital Management, KB Investment, Droia Ventures, Novartis Venture Fund, Eisai Innovation.
Hyku is headquartered in Lexington, United States.
Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins.
Hyku is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Hyku — Funding & Investors." VCBacked, September 19, 2023, https://www.vcbacked.co/company/hyku. Accessed July 23, 2026.
VCBacked. (2023). Hyku — Funding & Investors. Retrieved July 23, 2026, from https://www.vcbacked.co/company/hyku
{{cite web |title=Hyku — Funding & Investors |url=https://www.vcbacked.co/company/hyku |website=VCBacked |access-date=July 23, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated